Nyxoah (NASDAQ:NYXH – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03), Zacks reports. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%.
Nyxoah Trading Up 7.7 %
Shares of Nyxoah stock opened at $10.48 on Thursday. The company’s 50-day moving average price is $10.24 and its 200-day moving average price is $9.16. The company has a market cap of $356.78 million, a price-to-earnings ratio of -5.66 and a beta of 1.42. Nyxoah has a 12-month low of $6.76 and a 12-month high of $20.00. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Nyxoah in a research report on Friday, December 13th.
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Recommended Stories
- Five stocks we like better than Nyxoah
- Why Are These Companies Considered Blue Chips?
- Is a Bottom Finally Forming in Rocket Lab Stock?
- 3 Best Fintech Stocks for a Portfolio Boost
- Gold Rally vs. Oil Surge: Where Investors Are Betting Next
- There Are Different Types of Stock To Invest In
- Intel Stock Surges on New CEO – The Real Story Runs Deeper
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
